A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
4 Primary · 10 Secondary · Reporting Duration: 36 months
Experimental Treatment
75 Total Participants · 3 Treatment Groups
Primary Treatment: WTX-330 dose escalation · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: